Perseus Proteomics, Inc. (JP:4882) has released an update.
Perseus Proteomics Inc. has completed the Phase I clinical trial of its anti-transferrin receptor 1 antibody, PPMX-T003, for treating Polycythemia Vera, with no serious adverse events reported. The trial, which focused on safety and pharmacokinetics, concluded earlier than expected due to a patient’s decision to terminate their participation. The completion of the trial does not affect the company’s financial projections or licensing plans for the current fiscal year.
For further insights into JP:4882 stock, check out TipRanks’ Stock Analysis page.
